The American Academy of Otolaryngology-Head and Neck Surgery Foundation has published a supplement to this issue of Otolaryngology-Head and Neck Surgery featuring the ''Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update).'' To assist in implementing the guideline recommendations, this article summarizes the rationale, purpose, and key action statements. The 14 recommendations developed emphasize diagnostic accuracy and efficiency, reducing the inappropriate use of vestibular suppressant medications, decreasing the inappropriate use of ancillary testing, and increasing the appropriate therapeutic repositioning maneuvers. An updated guideline is needed due to new clinical trials, new systematic reviews, and the lack of consumer participation in the initial guideline development group.
Introduction
A primary complaint of dizziness accounts for 5.6 million clinic visits in the United States per year, and between 17% and 42% of patients with vertigo ultimately receive a diagnosis of benign paroxysmal positional vertigo (BPPV). [2] [3] [4] BPPV is a form of positional vertigo.
Vertigo is defined as an illusory sensation of motion of either the self or the surroundings in the absence of true motion. Positional vertigo is defined as a spinning sensation produced by changes in head position relative to gravity. BPPV is defined as a disorder of the inner ear characterized by repeated episodes of positional vertigo ( Table 1) .
Traditionally, the terms benign and paroxysmal have been used to characterize this particular form of positional vertigo. In this context, the descriptor benign historically implies that BPPV was a form of positional vertigo not due to any serious central nervous system disorder and that there was an overall favorable prognosis for recovery. 5 This favorable prognosis is based in part on the fact that BPPV can recover spontaneously in approximately 20% of patients by 1 month of follow-up and up to 50% at 3 months. 6, 7 However, the clinical and quality-of-life impacts of undiagnosed and untreated BPPV may be far from ''benign,'' as patients with BPPV are at increased risk for falls and impairment in the performance of daily activities. 8 Furthermore, patients with BPPV experience effects on individual healthrelated quality of life, and utility measures demonstrate that treatment of BPPV results in improvement in quality of life. 9 The term paroxysmal in this context describes the rapid and sudden onset of the vertigo initiated at any time by a change of position thus resulting in BPPV. BPPV has also been termed benign positional vertigo, paroxysmal positional vertigo, positional vertigo, benign paroxysmal nystagmus, and paroxysmal positional nystagmus. In this guideline, the panel chose to continue to retain the terminology of BPPV, as it is the most common terminology encountered in the literature and in clinical practice. 8 BPPV is most commonly clinically encountered as 1 of 2 variants: BPPV of the posterior semicircular canal (posterior canal BPPV) or BPPV of the lateral semicircular canal (also known as horizontal canal BPPV). [10] [11] [12] Posterior canal BPPV is more common than horizontal canal BPPV, constituting approximately 85% to 95% of BPPV cases. 12 Although debated, posterior canal BPPV is most commonly thought to be due to canalithiasis, wherein fragmented otolith particles (otoconia) entering the posterior canal become displaced and cause inertial changes to the cupula in the posterior canal and thereby result in abnormal nystagmus and vertigo when the head encounters motion in the plane of the affected semicircular canal. 12, 13 Lateral (horizontal) canal BPPV accounts for between 5% and 15% of BPPV cases. 11, 12 The etiology of lateral canal BPPV is also felt to be due to the presence of abnormal debris within the lateral canal, but the pathophysiology is not as well understood as that of posterior canal BPPV. Other rare variations include anterior canal BPPV, multicanal BPPV, and bilateral multicanal BPPV.
Guideline Purpose
The primary purposes of the guideline are to improve quality of care and outcomes for BPPV by improving the accurate and efficient diagnosis of BPPV, reducing the inappropriate use of vestibular suppressant medications, decreasing the inappropriate use of ancillary testing such as radiographic imaging, and increasing the use of appropriate therapeutic repositioning maneuvers. The guideline is intended for all clinicians who are likely to diagnose and manage patients with BPPV, and it applies to any setting in which BPPV would be identified, monitored, or managed. The target patient for the guideline is aged 18 years with a suspected or potential diagnosis of BPPV. The pediatric population was not included in the target population, in part due to a substantially smaller body of evidence on pediatric BPPV. No specific recommendations are made concerning surgical therapy for BPPV.
The guideline focuses on BPPV, recognizing that BPPV may arise in conjunction with other neurologic or otologic conditions and that the treatment of the symptom components specifically related to BPPV may still be managed according to the guideline. The guideline does not discuss BPPV affecting the anterior semicircular canal, as this diagnosis is quite rare and its pathophysiology is poorly understood. 14, 15 It also does not discuss benign paroxysmal vertigo of childhood, disabling positional vertigo due to vascular loop compression in the brainstem, or vertigo that arises from changes in head position not related to gravity (ie, vertigo of cervical origin or vertigo of vascular origin). These conditions are physiologically distinct from BPPV.
In 2008, the AAO-HNSF published a multidisciplinary clinical practice guideline: benign paroxysmal positional vertigo.
1 As 8 years have elapsed since the publication of that guideline, a multidisciplinary guideline update group was convened to perform an assessment and planned update of that guideline utilizing the most current evidence base. Our goal was to revise the prior guideline with an a priori determined, transparent process, reconsidering a more current evidence base while also taking into account advances in knowledge with respect to BPPV.
The primary outcome considered in the guideline is the resolution of the symptoms associated with BPPV. Secondary outcomes considered include an increased rate of accurate diagnoses of BPPV, a more efficient return to regular activities and work, decreased use of inappropriate medications and unnecessary diagnostic tests, reduction in recurrence of BPPV, and reduction in adverse events associated with undiagnosed or untreated BPPV. Other outcomes considered include minimizing costs in the diagnosis and treatment of BPPV, minimizing potentially unnecessary return physician visits, and maximizing the health-related quality of life of individuals afflicted with BPPV. The significant incidence of BPPV, its functional impact, and the wide diversities of diagnostic and therapeutic interventions for BPPV ( Table 2 ) make this an important condition for an up-to-date evidence-based practice guideline.
Methods

General Methods and Literature Search
In developing the update of the evidence-based clinical practice guideline, the methods outlined in the third edition of the AAO-HNSF's guideline development manual were followed explicitly. 16 An executive summary of the original BPPV guideline 1 was sent to a panel of expert reviewers from the fields of general otolaryngology, otology, neurotology, neurology, family practice, nursing, physical therapy, emergency medicine, radiology, audiology, and complementary medicine who assessed the key action statements to decide if they should be kept in their current form, revised, or removed and to identify new research that might affect the guideline recommendations. The reviewers concluded that the original guideline action statements remained valid but should be updated with minor modifications. Suggestions were also made for new key action statements.
An information specialist conducted 2 systematic literature searches using a validated filter strategy to identify clinical practice guidelines, systematic reviews, and RCTs published since the prior guideline (2008 guidelines were (a) an explicit scope and purpose, (b) multidisciplinary stakeholder involvement, (c) systematic literature review, (d) explicit system for ranking evidence, and (e) explicit system for linking evidence to recommendations. The final data set retained 2 guidelines that met inclusion criteria. 2. The initial search for systematic reviews identified 44 systematic reviews or meta-analyses that were distributed to the panel members. Quality criteria for including reviews were (a) relevance to the guideline topic, (b) clear objective and methodology, (c) explicit search strategy, and (d) valid data extraction methods. The final data set retained was 20 systematic reviews or meta-analyses that met inclusion criteria. 3. The initial search for RCTs identified 38 RCTs that were distributed to panel members for review. Quality criteria for including RCTs were (a) relevance to the guideline topic, (b) publication in a peer-reviewed journal, and (c) clear methodology with randomized allocation to treatment groups. The total final data set retained 27 RCTs that met inclusion criteria. The AAO-HNSF assembled a guideline update group representing the disciplines of otolaryngology-head and neck surgery, otology, neurotology, family medicine, audiology, emergency medicine, neurology, physical therapy, advanced practice nursing, and consumer advocacy. The guideline update group had several conference calls and 1 in-person meeting during which they defined the scope and objectives of updating the guideline, reviewed comments from the expert panel review for each key action statement, identified other quality improvement opportunities, and reviewed the literature search results.
The evidence profile for each statement in the earlier guideline was then converted into an expanded action statement profile for consistency with current development standards. 16 Information was added to the action statement profiles regarding the quality improvement opportunity to which the action statement pertained, the guideline panel's level of confidence in the published evidence, differences of opinion among panel members, intentional vagueness, and any exclusion to which the action statement does not apply. New key action statements were developed with an explicit and transparent a priori protocol for creating actionable statements based on supporting evidence and the associated balance of benefit and harm. Electronic decision support software (BRIDGE-Wiz; Yale Center for Medical Informatics, New Haven, Connecticut) was used to facilitate creating actionable recommendations and evidence profiles. 17 The updated guideline then underwent GuideLine Implementability Appraisal to appraise adherence to methodologic standards, to improve clarity of recommendations, and to predict potential obstacles to implementation. 18 The guideline update group received summary appraisals and modified an advanced draft of the guideline based on the appraisal. The final draft of the updated clinical practice guideline was revised according to comments received during multidisciplinary peer review, open public comment, and journal editorial peer review. A scheduled review process will occur at 5 years from publication or sooner if new compelling evidence warrants earlier consideration.
Classification of Evidence-Based Statements. Guidelines are intended to reduce inappropriate variations in clinical care, to produce optimal health outcomes for patients, and to minimize harm. The evidence-based approach to guideline development requires that the evidence supporting a policy be identified, appraised, and summarized and that an explicit link between evidence and statements be defined. Evidence-based statements reflect both the quality of evidence and the balance of benefit and harm that is anticipated when the statement is followed. Guidelines are never intended to supersede professional judgment; rather, they may be viewed as a relative constraint on individual clinician discretion in a particular clinical circumstance. Less frequent variation in practice is expected for a strong recommendation than what might be expected with a recommendation. Options offer the most opportunity for practice variability. 19 Clinicians should always act and decide in a way that they believe will best serve their individual patients' interests and needs, regardless of guideline recommendations. Guidelines represent the best judgment of a team of experienced clinicians and methodologists addressing the scientific evidence for a particular topic. 20 Making recommendations about health practices involves value judgments on the desirability of various outcomes associated with management options. Values applied by the guideline update group sought to minimize harm and diminish unnecessary and inappropriate therapy. A major goal of the panel was to be transparent and explicit about how values were applied and to document the process.
Financial Disclosure and Conflicts of Interest. The cost of developing this guideline, including travel expenses of all panel members, was covered in full by the AAO-HNSF. Potential conflicts of interest for all panel members in the past 5 years were compiled and distributed before the first conference call and were updated at each subsequent call and inperson meeting. 21 After review and discussion of these disclosures, the panel concluded that individuals with potential conflicts could remain on the panel if they (1) reminded the panel of potential conflicts before any related discussion, (2) recused themselves from a related discussion if asked by the panel, and (3) agreed not to discuss any aspect of the guideline with industry before publication. 21 Last, panelists were reminded that conflicts of interest extend beyond financial relationships and may include personal experiences, how a participant earns a living, and the participant's previously established ''stake'' in an issue. 22 
Guideline Key Action Statements
Each evidence-based statement is organized in a similar fashion: a key action statement is in bold, followed by the strength of the recommendation in italics. Each key action statement is followed by an ''action statement profile'' that explicitly states the quality improvement opportunity, aggregate evidence quality, level of confidence in evidence (high, medium, low), benefit, harms, risks, costs, and a benefitsharm assessment. Additionally, there are statements of any value judgments, the role of patient preferences, clarification of any intentional vagueness by the panel, exceptions to the statement, any differences of opinion, and a repeat statement of the strength of the recommendation. Several paragraphs subsequently discuss the evidence base supporting the statement. An overview of each evidence-based statement in this guideline can be found in Table 3 .
The role of patient preferences in making decisions deserves further clarification. The guideline update group classified the role of patient preference based on consensus among the group as ''none, small, moderate, or large.'' For some statements where the evidence base demonstrates clear benefit, although the role of patient preference for a range of treatments may not be relevant (eg, with intraoperative decision making), clinicians should provide patients with clear and comprehensible information on the benefits to facilitate patient understanding and shared decision making, which in turn leads to better patient adherence and outcomes. In cases where evidence is weak or benefits unclear, the practice of shared decision making-again where the management decision is made by a collaborative effort between the clinician and an informed patient-is extremely useful. Factors related to patient preference include (but are not limited to) absolute benefits, adverse effects, cost of drugs or procedures, and frequency and duration of treatment, as well as certain less tangible factors, such as religious and/or cultural beliefs or personal levels of desire for intervention.
STATEMENT 1a. DIAGNOSIS OF POSTERIOR SEMICIRCULAR CANAL BPPV: Clinicians should diagnose posterior semicircular canal BPPV when vertigo associated with torsional, upbeating nystagmus is provoked by the Dix-Hallpike maneuver, performed by bringing the patient from an upright to supine position with the head turned 45°to 1 side and neck extended 20°with the affected ear down. The maneuver should be repeated with the opposite ear down if the initial maneuver is negative. Strong recommendation based on diagnostic studies with minor limitations and a preponderance of benefit over harm. RADIOGRAPHIC TESTING: Clinicians should not obtain radiographic imaging in a patient who meets diagnostic criteria for BPPV in the absence of additional signs and/or symptoms inconsistent with BPPV that warrant imaging. Recommendation against radiographic imaging based on diagnostic studies with limitations and a preponderance of benefit over harm.
Action Statement Profile for Statement 1a
Action Statement Profile for Statement 3a
Quality improvement opportunity: Reduce unnecessary testing and costs, reduce unnecessary radiation and radiographic contrast exposure (National Quality Strategy domains: safety, affordable quality care) Aggregate evidence quality: Grade C, based on observational studies for radiographic imaging Level of confidence in evidence: Medium Benefits: Facilitate timely treatment by avoiding unnecessary testing associated with low yield and potential false-positive diagnoses; avoid radiation exposure and adverse reactions to testing Risks, harms, costs: None Benefits-harm assessment: Preponderance of benefit over harm Value judgments: The panel placed heavy value in the accuracy of the BPPV diagnosis at the outset in that a diagnosis made by appropriate history and Dix-Hallpike is adequate to proceed with management without further testing. 
Action Statement Profile for Statement 3b
Quality improvement opportunity: Reduce unnecessary testing and costs (National Quality Strategy domains: safety, affordable quality care) Aggregate evidence quality: Grade C, based on diagnostic studies with limitations in referred patient populations and observational studies for vestibular testing Level of confidence in evidence: Medium Benefits: Facilitate timely treatment by avoiding unnecessary testing associated with low yield and potential false-positive diagnoses; avoid patient discomfort from nausea and vomiting from vestibular testing; reduced costs from unnecessary testing Risks, harms, costs: None Benefits-harm assessment: Preponderance of benefit over harm 
Action Statement Profile
Quality improvement opportunity: To promote effective treatment of posterior canal BPPV (National Quality Strategy domain: promoting effective prevention/treatments) Aggregate evidence quality: Grade A, based on systematic reviews of RCTs Level of confidence in evidence: High for otolaryngology or subspecialty settings; lower in primary care settings where evidence is more limited Benefits: Prompt resolution of symptoms with a relatively low number needed to treat, ranging from 1 to 3 cases Risks, harms, costs: Transient provocation of symptoms of BPPV by the procedure; risk for falls due to imbalance after the procedure; no serious adverse events reported in RCTs Benefits-harm assessment: Preponderance of benefit over harm Value judgments: High value ascribed to prompt resolution of symptoms and the ease with which the CRP may be performed Intentional vagueness: None Role of patient preferences: Moderate Exceptions: Patients with physical limitations including cervical stenosis, Down's syndrome, severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, morbid obesity, ankylosing spondylitis, low back dysfunction, retinal detachment, carotid stenosis, and spinal cord injuries may not be candidates for this procedure or may need specialized examination tables for performance of the procedure. 
Action Statement Profile for Statement 4c
Quality improvement opportunity: Decreased costs due to less intervention and incorporating patient preferences (National Quality Strategy domains: engaging patients, affordable quality care) Aggregate evidence quality: Grade B, based on control groups from RCTs and observational studies with heterogeneity in follow-up and outcomes measures Level of confidence in evidence: High Benefits: Symptom resolution in 15% to 85% at 1 month without intervention Risks, harms, costs: Prolonged symptoms compared with other interventions that may expose patients to increased risks for falls or lost days of work; indirect costs of delayed resolution compared to other measures. Benefits-harm assessment: Relative balance of benefits and harms Value judgments: The panel felt strongly in favor of treatment with CRP rather than observation, particularly with respect to the value of an expedited time to symptom resolution. The panel felt that observation may not be suitable for older patients, patients with preexisting balance disorders, or individuals at high risks for falls. Intentional vagueness: Definition of follow-up is not explicitly specified.
Role of patient preferences: Large. Exceptions: None. Policy level: Option Differences of opinion: Some panel members thought that this option was not the optimal choice for management given the data for other interventions.
STATEMENT 5. VESTIBULAR REHABILITATION:
The clinician may offer vestibular rehabilitation in the treatment of BPPV. Option based on controlled observational studies and a balance of benefit and harm.
Action Statement Profile for Statement 5
Quality improvement opportunity: Offer additional therapy for patients with additional impairments, who fail initial CRP attempts, who are not candidates for CRP, and/or who refuse CRP; promoting effective therapy and increased patient safety (National Quality Strategy domains: safety, promoting effective prevention/treatment) Aggregate evidence quality: Grade B based on subset analysis of a systematic review and limited RCTs Level of confidence in evidence: Medium Benefits: Offer additional therapy for patients with additional impairments; prevention of falls, improved return of natural balance function Risks, harms, costs: No serious adverse events noted in published trials; transient provocation of BPPV symptoms during rehabilitation exercises; potential for delayed symptom resolution as compared with CRP as a sole intervention; need for repeated visits if done with clinician supervision; cost of therapy Benefits-harm assessment: Relative balance of benefits and harm Value judgments: The panel felt that vestibular rehabilitation, as defined in this guideline, may be better as an adjunctive therapy rather than a primary treatment modality. Subsets of patients with preexisting balance deficit, central nervous system disorders, or risk for falls may derive more benefit from vestibular rehabilitation than the patient with isolated BPPV. 
Action Statement Profile for Statement 6
Quality improvement opportunity: Decreased use of unnecessary medications with potentially harmful side effects; reduced costs (National Quality Strategy domains: safety, promoting effective prevention/treatment, affordable quality care) Aggregate evidence quality: Grade C based on observational and cross-sectional studies Level of confidence in evidence: Medium Benefits: Avoidance of adverse effects from or medication interactions with these medications; prevention of decreased diagnostic sensitivity from vestibular suppression during performance of the Dix-Hallpike maneuvers Risks, harms, costs: None Benefits-harm assessment: Preponderance of benefit over harm Value judgments: To avoid harm from ineffective treatments. The panel felt that data regarding harms and side effects from non-BPPV populations with vertigo would be applicable to the BPPV patient population. Intentional vagueness: The panel recognized that there most likely is a very small subgroup of patients with severe symptoms who may need vestibular suppression until more definitive treatment can be offered (eg, CRP) or immediately before and/or after treatment with CRP. Role of patient preferences: Small Exceptions: Severely symptomatic patients refusing other treatment options and patients requiring prophylaxis for CRP Policy level: Recommendation against Differences of opinion: None STATEMENT 7a. OUTCOME ASSESSMENT: Clinicians should reassess patients within 1 month after an initial period of observation or treatment to document resolution or persistence of symptoms. Recommendation based on observational outcomes studies and expert opinion and a preponderance of benefit over harm.
Action Statement Profile for Statement 7a
Quality improvement opportunity: Obtain outcomes data for treatment of BPPV; ability to assess treatment effectiveness (National Quality Strategy domains: safety, engaging patients, coordination of care, promoting effective prevention/treatment) Aggregate evidence quality: Grade C studies with known significant failure rates for an observation option and lower failure rates for CRP. Level 
Action Statement Profile for Statement 7b
Quality improvement opportunity: Capture missed or erroneous diagnoses; offer retreatment to those patients with early recurrence of BPPV or failed initial CRP (National Quality Strategy domain: safety, promoting effective prevention/treatment) Aggregate evidence quality: Grade A for treatment of observation failure and Grade B for CRP failure based on RCT and systematic review examining treatment responses and failure rates Level of confidence in evidence: Medium Benefits: Expedite effective treatment of patients with persistent BPPV and associated comorbidities; decrease the potential for missed serious medical conditions that require a different treatment algorithm Risks, harms, costs: Costs of reevaluation and the additional testing incurred Benefits-harm assessment: Preponderance of benefit over harm Value judgments: Valued comprehensive treatment of not only BPPV but associated conditions that affect balance and function. The panel also valued expeditiously treating cases of persistent BPPV following observation or vestibular rehabilitation with a CRP as more definitive therapy. Intentional vagueness: Characterization of persistent symptoms was intentionally vague to allow clinicians to determine the quality a degree of symptoms that should warrant further evaluation or retreatment. Role of patient preferences: Small Exceptions: None Policy level: Recommendation Differences of opinion: None STATEMENT 8. EDUCATION: Clinicians should educate patients regarding the impact of BPPV on their safety, the potential for disease recurrence, and the importance of follow-up. Recommendation based on observational studies of diagnostic outcomes and recurrence in patients with BPPV and a preponderance of benefit over harm.
Action Statement Profile for Statement 8
Quality improvement opportunity: Education allows patients to understand the implications of BPPV on quality of life and patient safety, especially falls (National Quality Strategy domains: safety, engaging patients, promoting effective prevention/treatment) Aggregate evidence quality: Grade C based on observational and cross-sectional studies of recurrence and fall risk Level of confidence in evidence: Medium Benefits: Increased awareness of fall risk, potentially decreasing injuries related to falls; increased patient awareness of BPPV recurrence, which allows prompt intervention Risks, harms, costs: None Benefits-harm assessment: Preponderance of benefit over harm Value judgments: None Intentional vagueness: None Role of patient preferences: None Exceptions: None Policy level: Recommendation Differences of opinion: None
Disclaimer
The clinical practice guideline is provided for information and educational purposes only. It is not intended as a sole source of guidance in managing BPPV. Rather, it is designed to assist clinicians by providing an evidence-based framework for decision-making strategies. The guideline is not intended to replace clinical judgment or establish a protocol for all individuals with this condition and may not provide the only appropriate approach to diagnosing and managing this program of care. As medical knowledge expands and technology advances, clinical indicators and guidelines are promoted as conditional and provisional proposals of what is recommended under specific conditions but are not absolute. Guidelines are not mandates; these do not and should not purport to be a legal standard of care. The responsible provider, in light of all circumstances presented by the individual patient, must determine the appropriate treatment. Adherence to these guidelines will not ensure successful patient outcomes in every situation. The AAO-HNSF emphasizes that these clinical guidelines should not be deemed to include all proper treatment decisions or methods of care or to exclude other treatment decisions or methods of care reasonably directed to obtaining the same results.
